Workflow
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say
INSMInsmed(INSM) ZACKS·2025-02-20 15:36

Core Insights - Insmed reported 104.44millioninrevenueforQ42024,ayear−over−yearincreaseof24.8104.44 million in revenue for Q4 2024, a year-over-year increase of 24.8% [1] - The EPS for the same period was -1.32, compared to -1.28ayearago,indicatingaslightdecline[1]−TherevenueexceededtheZacksConsensusEstimateby0.101.28 a year ago, indicating a slight decline [1] - The revenue exceeded the Zacks Consensus Estimate by 0.10%, while the EPS fell short by 14.78% [1] Revenue Breakdown - U.S. revenue was 67.80 million, slightly below the average estimate of 67.81million,reflectingayear−over−yearincreaseof16.467.81 million, reflecting a year-over-year increase of 16.4% [4] - Revenue from Europe and the rest of the world was 5.90 million, compared to an estimate of 5.93million,markingayear−over−yearincreaseof31.65.93 million, marking a year-over-year increase of 31.6% [4] - Revenue from Japan reached 30.70 million, close to the estimate of $30.72 million, with a year-over-year increase of 46.5% [4] Stock Performance - Insmed shares have returned +6.9% over the past month, outperforming the Zacks S&P 500 composite's +2.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]